Quote | Super Quote
Super Quote   |   Detail Quote   |   Interactive Chart   |   Transaction   |   Related News   |   Related Securities   |   Company Information   |   Dividend Records   |   Short Sell
01548 GENSCRIPT BIO
RTNominal up14.500 +0.300 (+2.113%)
Others

14/11/2018 17:50

[I-bank focus]JPM lowers Genscript Biotech (01548) to HK$28

[ET Net News Agency, 14 November 2018] J.P. Morgan lowered its target price for
Genscript Biotech Corporation (01548) to HK$28 from HK$37 and maintained its "overweight"
rating.
The research house said CAR-T development for multiple myeloma has been in line with
expectations, but JPM has seen Genscript announcing a number of initiatives in 2H (more
CAR-T pre-clinical trials, bispecific development, vaccine production and CMO). While
these new initiatives/businesses are likely to add to revenues and profits after three
years, they will likely add to research and development costs and lower profits for the
next three years.
Normally JPM said it would need to adjust its target price for the upside for these new
businesses. However, given current market conditions and negative sentiment, it has not
factored in significant value for these new businesses until they are closer to
commercialization. (KL)

Remark: Real time quote last updated: 28/03/2024 18:00
  Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service
A Member of HKET Holdings
Customer Service Hotline:(852) 2880 7004     Customer Service Email:cs@etnet.com.hk
Copyright 2024 ET Net Limited. http://www.etnet.com.hk ET Net Limited, HKEx Information Services Limited, its Holding Companies and/or any Subsidiaries of such holding companies, and Third Party Information Providers endeavour to ensure the availability, completeness, timeliness, accuracy and reliability of the information provided but do not guarantee its availability, completeness, timeliness, accuracy or reliability and accept no liability (whether in tort or contract or otherwise) any loss or damage arising directly or indirectly from any inaccuracies, interruption, incompleteness, delay, omissions, or any decision made or action taken by you or any third party in reliance upon the information provided. The quotes, charts, commentaries and buy/sell ratings on this website should be used as references only with your own discretion. ET Net Limited is not soliciting any subscriber or site visitor to execute any trade. Any trades executed following the commentaries and buy/sell ratings on this website are taken at your own risk for your own account.